Download PDF
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2018; 76(03): 139-144
DOI: 10.1590/0004-282X20180002
Article

The role of surgery in primary central nervous system lymphomas

El rol de la cirugía en los linfomas primarios del sistema nervioso central
Juan Francisco Villalonga
1   Fundación para la Lucha contas las Enfermedades Neurologicas de la Infancia, Departmento de Neurocirurgía, Buenos Aires, Argentina
,
Lucas Alessandro
1   Fundación para la Lucha contas las Enfermedades Neurologicas de la Infancia, Departmento de Neurocirurgía, Buenos Aires, Argentina
,
Mauricio Franco Farez
2   Center for Research on Neuroimmunological Diseases (CIEN), Buenos Aires, Argentina
3   Raúl Carrea Institute for Neurological Research (FLENI), Buenos Aires, Argentina
,
Rubén Mormandi
4   Raúl Carrea Institute for Neurological Research (FLENI), Departamento de Neurocirurgía, Buenos Aires, Argentina
,
Andrés Cervio
4   Raúl Carrea Institute for Neurological Research (FLENI), Departamento de Neurocirurgía, Buenos Aires, Argentina
,
Santiago Condomí Alcorta
1   Fundación para la Lucha contas las Enfermedades Neurologicas de la Infancia, Departmento de Neurocirurgía, Buenos Aires, Argentina
,
Alejandro Muggeri
1   Fundación para la Lucha contas las Enfermedades Neurologicas de la Infancia, Departmento de Neurocirurgía, Buenos Aires, Argentina
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

ABSTRACT

Background Primary central nervous system lymphomas (PCNSL) are infrequent. The traditional treatment of choice is chemotherapy. Complete resections have generally not been recommended, because of the risk of permanent central nervous system deficits with no proven improvement in survival. The aim of the current study was to compare survival among patients with PCNSL who underwent biopsy versus surgical resection.

Methods A retrospective study was conducted on 50 patients with a confirmed diagnosis of PCNSL treated at our center from January 1994 to July 2015.

Results Patients in the resection group exhibited significantly longer median survival time, relative to the biopsy group, surviving a median 31 months versus 14.5 months; p = 0.016.

Conclusions In our series, patients who had surgical resection of their tumor survived a median 16.5 months longer than patients who underwent biopsy alone.

RESUMO

Introducción Los linfomas primarios del sistema nervioso central (LPSNC) son infrecuentes. Tradicionalmente el tratamiento de elección es la quimioterapia. Existe un paradigma de no indicar resección, por el riesgo de déficit neurológico sin aumento de la sobrevida. El objetivo del presente estudio es comparar la sobrevida de pacientes con LPSNC sometidos a biopsia versus resección.

Métodos Estudio retrospectivo que incluye 50 pacientes con diagnóstico confirmado de LPSNC tratados en nuestra Institución desde enero de 1994 hasta julio de 2015.

Resultados Los pacientes del “grupo resección” mostraron una sobrevida media significativamente mayor respecto a los del “grupo biopsia”; 31 meses versus 14,5 meses respectivamente, p = 0,016.

Conclusiones En nuestra serie, los pacientes que con resección quirúrgica de su tumor tuvieron una sobrevida media de 16,5 meses superior que los pacientes biopsiados.

Keywords

lymphoma - therapeutics - biopsy - survival

Palavras-chave

linfoma - terapéutica - biopsia - sobrevivencia


Publication History

Received: 26 September 2017

Accepted: 09 December 2017

Article published online:
28 August 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Bailey P. Intracranial sarcomatous tumors of leptomeningeal origin. Arch Surg. 1929;18(4):1359-402. https://doi.org/10.1001/archsurg.1929.01140130449031.
  • 2 Henry JM, Heffner RR Jr, Dillard SH, Earle KM, Davis RL. Primary malignant lymphomas of the central nervous system. Cancer. 1974 Oct;34(4):1293-302. https://doi.org/10.1002/10970142(197410)34:4<1293::AID-CNCR2820340441>3.0.CO;2-P
  • 3 Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011 Oct;105(9):1414-8. https://doi.org/10.1038/bjc.2011.357
  • 4 Kluin PM, Deckert M, Ferry JA. Primary diffuse large B-cell lymphoma of the CNS. In: Swerdlow SH, editor. World Health Organization classification of tumours pathology and genetics of tumours of the haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. p. 240-4.
  • 5 Schabet M. Epidemiology of primary CNS lymphoma. J Neurooncol. 1999 Jul;43(3):199-201. https://doi.org/10.1023/A:1006290032052
  • 6 Kadan-Lottick NS, Skluzacek MC, Gurney JG. Decreasing incidence rates of primary central nervous system lymphoma. Cancer. 2002 Jul;95(1):193-202. https://doi.org/10.1002/cncr.10643
  • 7 Hunt MA, Jahnke K, Murillo TP, Neuwelt EA. Distinguishing primary central nervous system lymphoma from other central nervous system diseases: a neurosurgical perspective on diagnostic dilemmas and approaches. Neurosurg Focus. 2006 Nov;21(5):E3. https://doi.org/10.3171/foc.2006.21.5.4
  • 8 Fraser E, Gruenberg K, Rubenstein JL. New approaches in primary central nervous system lymphoma. Chin Clin Oncol. 2015 Mar;4(1):11. https://doi.org/10.3978/j.issn.2304-3865.2015.02.01
  • 9 Okita Y, Narita Y, Miyakita Y, Miyahara R, Ohno M, Takahashi M et al. Health-related quality of life in outpatients with primary central nervous system lymphoma after radiotherapy and high-dose methotrexate chemotherapy. Mol Clin Oncol. 2016 Sep;5(3):179-85. https://doi.org/10.3892/mco.2016.962
  • 10 Chamberlain MC. Long survival in patients with acquired immune deficiency syndrome-related primary central nervous system lymphoma. Cancer. 1994 Mar;73(6):1728-30. https://doi.org/10.1002/10970142(19940315)73:6<1728::AID-CNCR2820730629>3.0.CO;2-8
  • 11 Lai R, Rosenblum MK, DeAngelis LM. Primary CNS lymphoma: a whole-brain disease? Neurology. 2002 Nov;59(10):1557-62. https://doi.org/10.1212/01.WNL.0000034256.20173.EA
  • 12 Korfel A, Weller M, Martus P Roth P, Klasen HA, Roeth A et al. Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial. Ann Oncol. 2012 Sep;23(9):2374-80. https://doi.org/10.1093/annonc/mdr627
  • 13 Rubenstein JL, Gupta NK, Mannis GN, Lamarre AK, Treseler P. How I treat CNS lymphomas. Blood. 2013 Oct;122(14):2318-30. https://doi.org/10.1182/blood-2013-06-453084
  • 14 Wieduwilt MJ, Valles F, Issa S, Behler CM, Hwang J, McDermott M et al. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res. 2012 Feb;18(4):1146-55. https://doi.org/10.1158/1078-0432.CCR-11-0625
  • 15 Houang Xang K, Besell E, Bromberg J, Hottinger AF, Preusser M, Rudà R et al. Diagnosis and treatment of CNS lymphoma in inmunocompetent patients: guidelines from the European Association of Neuro-Oncology. Lancet Oncol. 2015;16(7):e322-32. https://doi.org/10.1016/S1470-2045(15)00076-5.
  • 16 Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. https://doi.org/10.1097/00000421-198212000-00014
  • 17 Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med. 1993 Dec;119(11):1093-104. https://doi.org/10.7326/0003-4819-119-11-199312010-00007
  • 18 Bhagavathi S, Wilson JD. Primary central nervous system lymphoma. Arch Pathol Lab Med. 2008 Nov;132(11):1830-4.
  • 19 Preusser M, Woehrer A, Koperek O, Rottenfusser A, Dieckmann K, Gatterbauer B et al. Primary central nervous system lymphoma: a clinicopathological study of 75 cases. Pathology. 2010;42(6):547-52. https://doi.org/10.3109/00313025.2010.508786
  • 20 Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May;127(20):2375-90. https://doi.org/10.1182/blood-2016-01-643569
  • 21 Bataille B, Delwail V, Menet E, Vandermarcq P Ingrand P, Wager M, et al. Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg. 2000 Feb;92(2):261-6. https://doi.org/10.3171/jns.2000.92.2.0261
  • 22 Bühring U, Herrlinger U, Krings T, Thiex R, Weller M, Küker W. MRI features of primary central nervous system lymphomas at presentation. Neurology. 2001 Aug;57(3):393-6. https://doi.org/10.1212/WNL.573.393
  • 23 Vaquero J, Martínez R, Rossi E, López R. Primary cerebral lymphoma: the “ghost tumor”. Case report. J Neurosurg. 1984 Jan;60(1):174-6. https://doi.org/10.3171/jns.1984.60.1.0174
  • 24 Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005 Jan;105(2):496-502. https://doi.org/10.1182/blood-2004-05-1982
  • 25 Weller M, Martus P, Roth P, Thiel E, Korfel A. Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro-oncol. 2012 Dec;14(12):1481-4. https://doi.org/10.1093/neuonc/nos159
  • 26 DeAngelis LM, Yahalom J, Heinemann MH, Cirrincione C, Thaler HT, Krol G. Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology. 1990 Jan;40(1):80-6. https://doi.org/10.1212/WNL.40.1.80
  • 27 Bellinzona M, Roser F, Ostertag H, Gaab RM, Saini M. Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases. Eur J Surg Oncol. 2005 Feb;31(1):100-5. https://doi.org/10.1016/j.ejso.2004.10.002
  • 28 Thiel E, Korfel A, Martus P Kanz L, Griesinger F, Rauch M et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010 Nov;11(11):1036-47. https://doi.org/10.1016/S1470-2045(10)70229-1